VARI-SU2C Epigenetics Dream Team launches new clinical trial to combat blood...
International collaboration pairs immunotherapy with an epigenetic drug to stop progression of chronic myelomonocytic leukemia and myelodysplastic syndrome into acute myeloid leukemia GRAND RAPIDS,...
View ArticleClik here to view.
Stand Up To Cancer awards $5.5 million to VARI for cancer clinical trials to...
Studies to test whether epigenetic and immunotherapy combination therapies can extend survivorship in lung and bladder cancers GRAND RAPIDS, Mich. (Oct. 12, 2017)—Van Andel Research Institute–Stand Up...
View ArticleA Catalyst for combating cancer
Nearly $5.5 million in grant funding to fuel collaborative clinical trials in lung and bladder cancers By Dr. Peter Jones and Dr. Steve Baylin Co-leaders, Van Andel Research Institute–Stand Up To...
View ArticleClik here to view.
Clinical trial investigates possible triple threat for lung cancer
A first-of-its-kind combination of medications may enable the immune system to better combat lung cancer, which claims more lives than any other cancer type and is responsible for more than 220,000...
View ArticleClik here to view.
Fighting cancer is a team effort
By Dr. Peter A. Jones and Dr. Steve Baylin Co-leaders, Van Andel Research Institute–Stand Up To Cancer Epigenetics Dream Team Four years ago, we embarked on a collaborative endeavor to improve cancer...
View ArticleFrom discovery to medicine Part three: What we’re doing to move lab...
In the past few weeks, VAI Voice has discussed what it takes to translate a promising laboratory discovery into a life-changing, approved treatment. In our final post in this three-part series, we’re...
View ArticleTune in Friday for the Stand Up To Cancer telecast
Keep a look out for Van Andel Institute’s Ann Schoen Van Andel Institute is delighted to be a part of the 2018 Stand Up To Cancer (SU2C) telecast on Friday, Sept. 7, at 8 p.m. Eastern. Keep an eye out...
View ArticleThat’s a wrap! Van Andel Research Institute featured in Stand Up To Cancer...
Last Friday was a day to remember, one that will affect lives for years to come. We were thrilled to be a part of the 2018 Stand Up To Cancer (SU2C) telecast, which raised a record-breaking $123...
View ArticleClik here to view.
Three Van Andel Research Institute scientists named to list of most cited...
GRAND RAPIDS, Mich. (Dec. 21, 2018) — Van Andel Research Institute-affiliated scientists Peter W. Laird, Ph.D., Stephen B. Baylin, M.D., and H. Eric Xu, Ph.D., are included in this year’s Highly Cited...
View ArticleClik here to view.
Blocking epigenetic “Swiss army knife” may be a new strategy for treating...
GRAND RAPIDS, Mich. (April 4, 2019) — A new study out today in Cancer Cell shows that blocking specific regions of a protein called UHRF1 switches on hundreds of cancer-fighting genes, impairing...
View Article
